Health Care [ 12/12 ] | Biotechnology [ 69/75 ]
NASDAQ | Common Stock
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors.
The company is headquartered in Doylestown, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 24 | -0.58 Increased by +33.33% | -0.63 Increased by +7.94% |
| May 14, 24 | -0.67 Increased by +50.00% | -0.78 Increased by +14.10% |
| Mar 26, 24 | -0.92 Increased by 0.00% | -0.77 Decreased by -19.48% |
| Nov 9, 23 | -0.86 Increased by +64.17% | -1.16 Increased by +25.86% |
| Aug 10, 23 | -0.87 Increased by +95.56% | -1.42 Increased by +38.73% |
| May 15, 23 | -1.34 Increased by +81.39% | -1.50 Increased by +10.67% |
| Mar 30, 23 | -0.92 Increased by +87.22% | -3.08 Increased by +70.13% |
| Nov 9, 22 | -2.40 Increased by +73.33% | -5.50 Increased by +56.36% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 561.57 K Increased by +124.91% | -3.47 M Decreased by -6.47% | Decreased by -617.92% Increased by +52.66% |
| Mar 31, 24 | 380.57 K Increased by +N/A% | -2.81 M Increased by +32.30% | Decreased by -738.39% Decreased by N/A% |
| Dec 31, 23 | 14.07 K Increased by +N/A% | -3.44 M Increased by +96.89% | Decreased by -24.46 K% Decreased by N/A% |
| Sep 30, 23 | 319.47 K Increased by +N/A% | -3.20 M Increased by +23.26% | Decreased by -1.00 K% Decreased by N/A% |
| Jun 30, 23 | 249.69 K Increased by +N/A% | -3.26 M Increased by +96.68% | Decreased by -1.31 K% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -4.15 M Increased by +47.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -110.78 M Decreased by -1.33 K% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -4.18 M Increased by +55.82% | Decreased by N/A% Decreased by N/A% |